Furthermore, given the previously established role for PAR2 in nociception (7), there is now substantial evidence to support the therapeutic targeting of this receptor to combat pain as well as inflammation and joint destruction and in the rheumatic diseases. This evidence concerns the gene F2RL1 and rheumatic disorder.